JP2022512156A5 - - Google Patents
Info
- Publication number
- JP2022512156A5 JP2022512156A5 JP2021532487A JP2021532487A JP2022512156A5 JP 2022512156 A5 JP2022512156 A5 JP 2022512156A5 JP 2021532487 A JP2021532487 A JP 2021532487A JP 2021532487 A JP2021532487 A JP 2021532487A JP 2022512156 A5 JP2022512156 A5 JP 2022512156A5
- Authority
- JP
- Japan
- Prior art keywords
- cycloalkyl
- heterocyclyl
- heteroaryl
- crosslinked
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025086518A JP2025116052A (ja) | 2018-12-10 | 2025-05-23 | メチオニンアデノシルトランスフェラーゼ２ａインヒビターとしての２－オキソキナゾリン誘導体 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862777715P | 2018-12-10 | 2018-12-10 | |
| US62/777,715 | 2018-12-10 | ||
| US201962835853P | 2019-04-18 | 2019-04-18 | |
| US62/835,853 | 2019-04-18 | ||
| US201962883945P | 2019-08-07 | 2019-08-07 | |
| US62/883,945 | 2019-08-07 | ||
| PCT/US2019/065260 WO2020123395A1 (en) | 2018-12-10 | 2019-12-09 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025086518A Division JP2025116052A (ja) | 2018-12-10 | 2025-05-23 | メチオニンアデノシルトランスフェラーゼ２ａインヒビターとしての２－オキソキナゾリン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022512156A JP2022512156A (ja) | 2022-02-02 |
| JP2022512156A5 true JP2022512156A5 (https=) | 2022-12-16 |
| JP7688578B2 JP7688578B2 (ja) | 2025-06-04 |
Family
ID=69138003
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021532487A Active JP7688578B2 (ja) | 2018-12-10 | 2019-12-09 | メチオニンアデノシルトランスフェラーゼ２ａインヒビターとしての２－オキソキナゾリン誘導体 |
| JP2025086518A Pending JP2025116052A (ja) | 2018-12-10 | 2025-05-23 | メチオニンアデノシルトランスフェラーゼ２ａインヒビターとしての２－オキソキナゾリン誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025086518A Pending JP2025116052A (ja) | 2018-12-10 | 2025-05-23 | メチオニンアデノシルトランスフェラーゼ２ａインヒビターとしての２－オキソキナゾリン誘導体 |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US12503467B2 (https=) |
| EP (1) | EP3894396A1 (https=) |
| JP (2) | JP7688578B2 (https=) |
| KR (1) | KR20210103498A (https=) |
| CN (2) | CN119528824A (https=) |
| AU (1) | AU2019395338B2 (https=) |
| BR (1) | BR112021010842A2 (https=) |
| CA (1) | CA3121236A1 (https=) |
| CL (1) | CL2021001508A1 (https=) |
| CO (1) | CO2021008895A2 (https=) |
| IL (1) | IL283743A (https=) |
| MA (1) | MA54452A (https=) |
| MX (1) | MX2021006841A (https=) |
| PH (1) | PH12021551274A1 (https=) |
| SG (1) | SG11202105469YA (https=) |
| TW (1) | TWI863945B (https=) |
| WO (1) | WO2020123395A1 (https=) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020123395A1 (en) | 2018-12-10 | 2020-06-18 | Ideaya Biosciences, Inc. | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors |
| SG11202108519TA (en) | 2019-02-13 | 2021-09-29 | Ptc Therapeutics Inc | Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia |
| WO2020167624A1 (en) | 2019-02-13 | 2020-08-20 | Ptc Therapeutics, Inc. | Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia |
| JP7736700B2 (ja) * | 2020-02-28 | 2025-09-09 | リミックス セラピューティクス インコーポレイテッド | 複素環アミド及びスプライシングを調節するためのその使用 |
| US20240208965A1 (en) * | 2020-06-10 | 2024-06-27 | Ideaya Biosciences, Inc. | Heteroaryl alkylene substituted 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors |
| IL297879A (en) * | 2020-06-22 | 2023-01-01 | Hoffmann La Roche | Amidopyrimidone derivatives |
| KR20230026479A (ko) | 2020-06-22 | 2023-02-24 | 에프. 호프만-라 로슈 아게 | 설폰 유도체 |
| CN116406271B (zh) * | 2020-07-14 | 2024-09-24 | 南京再明医药有限公司 | 双环类化合物 |
| EP4210833A4 (en) | 2020-09-11 | 2024-09-11 | Mirati Therapeutics, Inc. | CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR |
| WO2022063128A1 (zh) * | 2020-09-24 | 2022-03-31 | 上海凌达生物医药有限公司 | 一类芳环或芳基杂环并吡啶酮类化合物、药物组合物及其应用 |
| CA3201663A1 (en) | 2020-11-20 | 2022-05-27 | Amgen Inc. | Process for preparing 7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione |
| JP2023553492A (ja) * | 2020-12-15 | 2023-12-21 | ミラティ セラピューティクス， インコーポレイテッド | アザキナゾリン汎ＫＲａｓ阻害剤 |
| EP4262803A4 (en) | 2020-12-16 | 2025-03-12 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-kras inhibitors |
| US20240124454A1 (en) | 2020-12-31 | 2024-04-18 | Nanjing Zaiming Pharmaceutical Co., Ltd. | Tricyclic compound and use thereof |
| WO2022206730A1 (zh) * | 2021-03-29 | 2022-10-06 | 武汉人福创新药物研发中心有限公司 | 嘧啶并吡嗪酮化合物及其用途 |
| WO2022222911A1 (zh) * | 2021-04-19 | 2022-10-27 | 武汉人福创新药物研发中心有限公司 | 嘧啶酮化合物及其用途 |
| JP2024516429A (ja) * | 2021-04-30 | 2024-04-15 | サイノハブ ファーマシューティカル カンパニー リミテッド | メチオニンアデノシルトランスフェラーゼ阻害剤、その調製方法およびその適用 |
| WO2022256808A1 (en) * | 2021-06-02 | 2022-12-08 | Ideaya Biosciences Inc. | Combination therapy comprising a mat2a inhibitor and type i prmt inhibitor |
| EP4347569A4 (en) * | 2021-06-02 | 2025-03-26 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a type ii prmt inhibitor |
| CN117412967A (zh) * | 2021-06-02 | 2024-01-16 | 南京正大天晴制药有限公司 | 蛋氨酸腺苷转移酶2a抑制剂 |
| US12054486B2 (en) | 2021-09-24 | 2024-08-06 | Xenon Pharmaceuticals Inc. | Pyridine derivatives and their use as sodium channel activators |
| AR127404A1 (es) * | 2021-10-20 | 2024-01-17 | Insilico Medicine Ip Ltd | Inhibidores de la metionina adenosiltransferasa 2a (mat2a) y usos de los mismos |
| CN118265700A (zh) * | 2021-11-09 | 2024-06-28 | 上海海雁医药科技有限公司 | 取代的萘啶酮衍生物、其药物组合物及应用 |
| US20250090533A1 (en) * | 2021-11-12 | 2025-03-20 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a taxane |
| CN118414338A (zh) * | 2021-12-21 | 2024-07-30 | 南京正大天晴制药有限公司 | 蛋氨酸腺苷转移酶2a的杂环抑制剂 |
| JP2025503186A (ja) * | 2022-01-26 | 2025-01-30 | 勤浩医▲葯▼（▲蘇▼州）有限公司 | Ｍｔａｐ欠失型がん治療用メチオニンアデノシルトランスフェラーゼ２ａ阻害剤 |
| WO2023177894A1 (en) | 2022-03-18 | 2023-09-21 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and an antimetabolite agent |
| WO2023185811A1 (zh) | 2022-03-29 | 2023-10-05 | 首药控股(北京)股份有限公司 | 一种新型杂环化合物 |
| GB202204913D0 (en) | 2022-04-04 | 2022-05-18 | Cambridge Entpr Ltd | antiviral therapy |
| WO2023201338A1 (en) | 2022-04-15 | 2023-10-19 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a parp inhibitor |
| JP2025521737A (ja) | 2022-06-27 | 2025-07-10 | 石▲薬▼集▲團▼中奇制▲薬▼技▲術▼（石家庄）有限公司 | 三環式化合物およびその使用 |
| CN117430596A (zh) * | 2022-07-13 | 2024-01-23 | 上海海和药物研究开发股份有限公司 | 二并环类mat2a抑制剂及其用途 |
| AU2023361063A1 (en) | 2022-10-13 | 2025-04-17 | Hanmi Pharm. Co., Ltd. | Novel tricyclic derivative compound and uses thereof |
| TW202440126A (zh) | 2022-11-30 | 2024-10-16 | 美商安進公司 | 利用ｍｔａ協作的ｐｒｍｔ５抑制劑和ｍａｔ２ａ抑制劑之癌症治療 |
| JP2025540086A (ja) * | 2022-11-30 | 2025-12-11 | アイディアヤ バイオサイエンシーズ，インコーポレイティド | ２－オキソキナゾリン結晶形態 |
| EP4626887A1 (en) * | 2022-11-30 | 2025-10-08 | Ideaya Biosciences, Inc. | Atropisomers of mat2a inhibitors |
| WO2024118943A2 (en) * | 2022-11-30 | 2024-06-06 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a prmt5 inhibitor |
| CN116425751B (zh) * | 2022-12-19 | 2024-01-23 | 艾立康药业股份有限公司 | 作为mat2a抑制剂的多环类化合物 |
| WO2024217502A1 (en) * | 2023-04-19 | 2024-10-24 | Insilico Medicine Ip Limited | Methionine adenosyltransferase 2a (mat2a) inhibitor combinations and uses thereof |
| KR20250174628A (ko) * | 2023-04-19 | 2025-12-12 | 인실리코 메디신 아이피 리미티드 | 결정성 메티오닌 아데노실트랜스퍼라제 2a (MAT2A) 억제제 및 이의 용도 |
| CN116283800B (zh) * | 2023-05-16 | 2023-07-18 | 英矽智能科技(上海)有限公司 | 氧代喹唑啉类化合物及其应用 |
| CN121586715A (zh) * | 2023-06-14 | 2026-02-27 | 南京正大天晴制药有限公司 | 蛋氨酸腺苷转移酶2a杂环抑制剂的盐、晶型及其制备方法 |
| CN116478172B (zh) * | 2023-06-20 | 2023-09-05 | 英矽智能科技(上海)有限公司 | 吡咯并[3,2-d]嘧啶类化合物及其应用 |
| WO2025059579A1 (en) | 2023-09-15 | 2025-03-20 | Ideaya Biosciences, Inc. | Methods of treating mat2a related diseases |
| WO2025064750A1 (en) | 2023-09-20 | 2025-03-27 | Ideaya Biosciences, Inc. | Combination therapy with a parg inhibitor |
| WO2025072544A1 (en) | 2023-09-27 | 2025-04-03 | Ideaya Biosciences, Inc. | Sulfonamino indazole compounds as inhibitors of parg |
| WO2025166260A1 (en) | 2024-02-02 | 2025-08-07 | Ideaya Biosciences, Inc. | Amide substituted tricyclic guanidino compounds as prmt5 inhibitors |
| WO2025166215A1 (en) | 2024-02-02 | 2025-08-07 | Ideaya Biosciences, Inc. | Triheterocyclic guanidino compounds as prmt5 inhibitors |
| WO2025166274A1 (en) | 2024-02-02 | 2025-08-07 | Ideaya Biosciences, Inc. | Tricyclic guanidino compounds as prmt5 inhibitors |
| WO2025166229A1 (en) | 2024-02-02 | 2025-08-07 | Ideaya Biosciences, Inc. | Tricyclic amidino compounds as prmt5 inhibitors |
| WO2025166257A1 (en) | 2024-02-02 | 2025-08-07 | Ideaya Biosciences, Inc. | Amide substituted triheterocyclic guanidino compounds as prmt5 inhibitors |
| WO2025223561A1 (zh) * | 2024-04-26 | 2025-10-30 | 中国科学院上海药物研究所 | 一种喹唑啉酮并五元杂环化合物及其药用组合物和用途 |
| WO2025250569A1 (en) | 2024-05-29 | 2025-12-04 | Amgen Inc. | Cancer treatments using mta-cooperative prmt5 inhibitors and mat2a inhibitors |
| CN118724899B (zh) * | 2024-07-03 | 2025-09-30 | 中国药科大学 | 2(1h)-喹喔啉酮化合物、其药物组合物及应用 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3202661A (en) | 1962-11-27 | 1965-08-24 | Hoffmann La Roche | Substituted 3-amino 4-phenyl quinolones |
| US4096144A (en) | 1970-12-08 | 1978-06-20 | Sumitomo Chemical Company, Limited | Process for preparing quinazolinone derivatives and their 2-(N-mono-substituted amino)-phenyl ketone intermediate derivatives |
| JPS5761758B2 (https=) | 1974-01-11 | 1982-12-25 | Hisamitsu Pharmaceutical Co | |
| WO1994007498A1 (fr) | 1992-10-07 | 1994-04-14 | Sumitomo Pharmaceuticals Company, Limited | Composition pharmaceutique utilisee pour inhiber la production des facteurs de necrose tumorale |
| EP0759454B1 (en) | 1994-05-11 | 2002-03-06 | Asahi Kasei Kabushiki Kaisha | para-ORIENTED AROMATIC POLYAMIDE MOLDING AND PROCESS FOR PRODUCING THE SAME |
| US5525711A (en) * | 1994-05-18 | 1996-06-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pteridine nucleotide analogs as fluorescent DNA probes |
| NZ322197A (en) | 1995-11-21 | 1999-02-25 | Yamanouchi Pharma Co Ltd | Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof |
| TW504504B (en) | 1996-11-26 | 2002-10-01 | Bristol Myers Squibb Co | 4-aryl-3-hydroxyquinolin-2-one derivatives as ion channel modulators |
| AU742452B2 (en) | 1997-08-28 | 2002-01-03 | Bristol-Myers Squibb Company | 4-aryl-3-aminoquinoline-2-one derivatives as potassium channel modulators |
| PA8539401A1 (es) | 2001-02-14 | 2002-10-28 | Warner Lambert Co | Quinazolinas como inhibidores de mmp-13 |
| AR038658A1 (es) | 2001-06-15 | 2005-01-26 | Novartis Ag | Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento |
| US7098332B2 (en) | 2002-12-20 | 2006-08-29 | Hoffmann-La Roche Inc. | 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones |
| WO2004065542A2 (en) | 2002-12-30 | 2004-08-05 | Exelixis, Inc. | MAT2As AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE |
| WO2005020885A2 (en) | 2003-05-21 | 2005-03-10 | Isis Pharmaceuticals, Inc. | Compositions and methods for the treatment of severe acute respiratory syndrome (sars) |
| US7049309B2 (en) | 2003-10-14 | 2006-05-23 | Bristol-Myers Squibb Company | 3-Thia-4-arylquinolin-2-one potassium channel modulators |
| US8338435B2 (en) | 2006-07-20 | 2012-12-25 | Gilead Sciences, Inc. | Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections |
| RU2477046C2 (ru) | 2006-11-22 | 2013-03-10 | Сумитомо Кемикал Компани, Лимитед | Агент для ингибирования сигнальной функции цитокинина |
| US7928111B2 (en) | 2007-06-08 | 2011-04-19 | Senomyx, Inc. | Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors |
| EP2266984A1 (en) | 2009-06-26 | 2010-12-29 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Pyrido[2,3-d]pyrimidines as Wnt antagonists for treatment of cancer and arthritis |
| CN101671336B (zh) | 2009-09-23 | 2013-11-13 | 辽宁利锋科技开发有限公司 | 芳杂环并嘧啶衍生物和类似物及其制备方法和用途 |
| EP4166558A1 (en) | 2010-02-12 | 2023-04-19 | Pfizer Inc. | Salts and polymorphs of 8-fluoro-2-{4- [(methylamino)methyl]phenyl}-1 ,3,4,5-tetrahydro-6h-azepino[5,4,3- cd]indol-6-one |
| PT2611797T (pt) * | 2010-08-31 | 2017-02-07 | Hanmi Science Co Ltd | Derivados de quinolina ou de quinazolina com atividade indutora de apoptose nas células |
| CN110015962B (zh) | 2011-01-28 | 2022-03-15 | 肯塔基大学研究基金会 | 茋类似物和治疗癌症的方法 |
| JP2014519340A (ja) | 2011-06-16 | 2014-08-14 | カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． | バイオマーカー組成物および方法 |
| CN103842364A (zh) | 2011-09-30 | 2014-06-04 | 奇尼塔公司 | 抗病毒化合物 |
| CN104011050A (zh) * | 2011-12-22 | 2014-08-27 | 霍夫曼-拉罗奇有限公司 | 作为丝氨酸/苏氨酸激酶抑制剂的2,4-二氨基-嘧啶衍生物 |
| CN102816197B (zh) | 2012-08-24 | 2015-04-29 | 四川大学华西医院 | 一种新的嘧啶并嘧啶类核苷类似物、制备方法及其形成的超分子结构和应用 |
| EA201591746A1 (ru) | 2013-03-14 | 2016-08-31 | КОНВЕРДЖЕН ЭлЭлСи | Способы и композиции для ингибирования бромодомен-содержащих белков |
| WO2017096165A1 (en) | 2015-12-03 | 2017-06-08 | Agios Pharmaceuticals, Inc. | Mat2a inhibitors for treating mtap null cancer |
| KR102470130B1 (ko) | 2016-07-18 | 2022-11-24 | 내셔널 인스티튜트 오브 바이올로지칼 사이언시스, 베이징 | 아폽토시스 억제제 |
| JP6832430B2 (ja) | 2016-08-31 | 2021-02-24 | アジオス ファーマシューティカルズ， インコーポレイテッド | 細胞代謝過程の阻害剤 |
| WO2018039772A1 (en) | 2016-09-02 | 2018-03-08 | FutureVault Inc. | Real-time document filtering systems and methods |
| CN110366550A (zh) | 2016-12-22 | 2019-10-22 | 美国安进公司 | 作为用于治疗肺癌、胰腺癌或结直肠癌的KRAS G12C抑制剂的苯并异噻唑、异噻唑并[3,4-b]吡啶、喹唑啉、酞嗪、吡啶并[2,3-d]哒嗪和吡啶并[2,3-d]嘧啶衍生物 |
| AU2018273356B2 (en) | 2017-05-22 | 2021-09-16 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| US11161839B2 (en) * | 2017-05-26 | 2021-11-02 | The Institute Of Cancer Research: Royal Cancer Hospital | 2-quinolone derived inhibitors of BCL6 |
| WO2018221433A1 (ja) | 2017-05-29 | 2018-12-06 | 第一三共株式会社 | ヘテロアリールアミン誘導体 |
| AU2018329920B2 (en) | 2017-09-08 | 2022-12-01 | Amgen Inc. | Inhibitors of KRAS G12C and methods of using the same |
| US11524960B2 (en) | 2018-03-30 | 2022-12-13 | Servier Pharmaceuticals Llc | Heterobicyclic inhibitors of MAT2A and methods of use for treating cancer |
| CA3098574A1 (en) | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| US11285156B2 (en) | 2018-06-12 | 2022-03-29 | Amgen Inc. | Substituted piperazines as KRAS G12C inhibitors |
| GB2575490A (en) | 2018-07-12 | 2020-01-15 | Recordati Ind Chimica E Farmaceutica Spa | P2X3 receptor antagonists |
| US11376256B2 (en) | 2018-07-19 | 2022-07-05 | Agency For Science, Technology And Research | Method of treating a methionine-dependent cancer |
| EP3887373A1 (en) | 2018-11-29 | 2021-10-06 | Araxes Pharma LLC | Compounds and methods of use thereof for treatment of cancer |
| WO2020123395A1 (en) | 2018-12-10 | 2020-06-18 | Ideaya Biosciences, Inc. | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors |
| LT3902803T (lt) | 2018-12-27 | 2023-04-25 | Les Laboratoires Servier | Aza-heterobicikliniai mat2a inhibitoriai ir būdai, skirti panaudoti vėžio gydymui |
| EA202191800A1 (ru) | 2018-12-27 | 2021-09-13 | Ле Лаборатуар Сервье Сас | Азагетеробициклические ингибиторы мат2а и способы их применения для нацеливания на рак |
| US20240208965A1 (en) | 2020-06-10 | 2024-06-27 | Ideaya Biosciences, Inc. | Heteroaryl alkylene substituted 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors |
| WO2021252680A1 (en) | 2020-06-10 | 2021-12-16 | Ideaya Biosciences, Inc. | 4-arylquinazoline derivatives as methionine adenosyltransferase 2a inhibitors |
| EP4165040B1 (en) | 2020-06-10 | 2025-08-27 | Ideaya Biosciences, Inc. | 2-aminoquinazolinone derivatives as methionine adenosyltransferase 2a inhibitors |
| US20230227409A1 (en) | 2020-06-10 | 2023-07-20 | Ideaya Biosciences, Inc. | Quinolinone derivatives as methionine adenosyltransferase 2a inhibitors |
| TW202227082A (zh) | 2020-08-12 | 2022-07-16 | 美商施維雅製藥有限公司 | 用於治療癌症之組合療法 |
| WO2022053908A1 (ja) | 2020-09-11 | 2022-03-17 | 株式会社半導体エネルギー研究所 | 表示装置、表示モジュール、及び電子機器 |
| EP4347569A4 (en) | 2021-06-02 | 2025-03-26 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a type ii prmt inhibitor |
| US20250090533A1 (en) | 2021-11-12 | 2025-03-20 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a taxane |
| WO2023196985A1 (en) | 2022-04-08 | 2023-10-12 | Ideaya Biosciences, Inc. | Methionine adenosyltransferase 2a inhibitors |
| WO2023201338A1 (en) | 2022-04-15 | 2023-10-19 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a parp inhibitor |
| EP4626887A1 (en) | 2022-11-30 | 2025-10-08 | Ideaya Biosciences, Inc. | Atropisomers of mat2a inhibitors |
-
2019
- 2019-12-09 WO PCT/US2019/065260 patent/WO2020123395A1/en not_active Ceased
- 2019-12-09 JP JP2021532487A patent/JP7688578B2/ja active Active
- 2019-12-09 CA CA3121236A patent/CA3121236A1/en active Pending
- 2019-12-09 US US17/311,873 patent/US12503467B2/en active Active
- 2019-12-09 EP EP19832505.2A patent/EP3894396A1/en active Pending
- 2019-12-09 CN CN202411684986.9A patent/CN119528824A/zh active Pending
- 2019-12-09 BR BR112021010842-4A patent/BR112021010842A2/pt unknown
- 2019-12-09 MA MA054452A patent/MA54452A/fr unknown
- 2019-12-09 SG SG11202105469YA patent/SG11202105469YA/en unknown
- 2019-12-09 CN CN201980081299.9A patent/CN113166078B/zh active Active
- 2019-12-09 KR KR1020217021424A patent/KR20210103498A/ko active Pending
- 2019-12-09 MX MX2021006841A patent/MX2021006841A/es unknown
- 2019-12-09 AU AU2019395338A patent/AU2019395338B2/en active Active
- 2019-12-10 TW TW108145188A patent/TWI863945B/zh active
-
2021
- 2021-02-12 US US17/175,581 patent/US11130759B1/en active Active
- 2021-02-12 US US17/175,578 patent/US11046691B1/en active Active
- 2021-02-12 US US17/175,579 patent/US11084798B1/en active Active
- 2021-05-31 PH PH12021551274A patent/PH12021551274A1/en unknown
- 2021-06-06 IL IL283743A patent/IL283743A/en unknown
- 2021-06-09 CL CL2021001508A patent/CL2021001508A1/es unknown
- 2021-07-06 CO CONC2021/0008895A patent/CO2021008895A2/es unknown
-
2025
- 2025-05-23 JP JP2025086518A patent/JP2025116052A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022512156A5 (https=) | ||
| RU2354653C2 (ru) | Производные 1-(2-аминобензол)пиперазина, используемые в качестве ингибиторов поглощения глицина и предназначенные для лечения психоза | |
| RU2002123350A (ru) | Дипептиднитрильные ингибиторы катепсина К | |
| RU2436780C2 (ru) | Производные 5-фенилтиазола и их применение в качестве ингибиторов рi3 киназы | |
| RU2264389C2 (ru) | Азотсодержащие ароматические производные, их применение, лекарственное средство на их основе и способ лечения | |
| JP2024519170A5 (https=) | ||
| JP2020037585A5 (https=) | ||
| JP2003502405A5 (https=) | ||
| IL269710B2 (en) | 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in cancer therapy | |
| JP2012520867A5 (https=) | ||
| CY1107433T1 (el) | Παραγωγα 1-(2η-πυραζολ-3-υλο)-3-(4-[1-(βενζοϋλο)-πιπepιδιν-4-υλομεθυλο]-φαινυλο)-ουριας και συναφεις ενωσεις ως αναστολεις της ρ38 κινασης και/ή tnf-αναστολεις για την αντιμετωπιση φλεγμονων | |
| KR101763273B1 (ko) | 4 위치 치환 피라졸로피리미딘 유도체 및 약학 제제로서의 이의 용도 | |
| RU2019120990A (ru) | Бициклические гетероарильные производные в качестве стимуляторов cftr | |
| JP2012519179A5 (https=) | ||
| RU2012110007A (ru) | Имидазохинолины в качестве двойных ингибиторов липидкиназы и mtor | |
| RU2006134020A (ru) | Конденсированные производные пиразола | |
| RU2005117340A (ru) | Производные пиримидо {4,5-d}пиримидина, обладающие противораковой активностью | |
| JP2004525150A5 (https=) | ||
| JP2005539088A5 (https=) | ||
| RU2011139321A (ru) | Модулирующие jak киназу хиназолиновые производные и способы их применения | |
| JP2003535887A5 (https=) | ||
| JP2005537313A5 (https=) | ||
| KR920018037A (ko) | 4-아릴-티아졸 또는 이미다졸 유도체 | |
| JP2010517946A5 (https=) | ||
| JP2018507899A5 (https=) |